Yuqin Tang

Yuqin Tang

Auto-generated profile, based on publicly available information

Yuqin Tang

Department of Anesthesiology and Perioperative Medicine Henan Provincial People's Hospital People's Hospital of Zhengzhou University Zhengzhou China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
CGChengbin Guo
Chengbin Guo
YTYuqin Tang
Yuqin Tang
QLQizhuo Li
Qizhuo Li
ZYZhao Yang
Zhao Yang
YGYuqi Guo
Yuqi Guo
YZYongqiang Zhang
Yongqiang Zhang

1 July 2023 in Genes & Diseases
Verified
Journal Article
Open access
YZYongqiang Zhang
Yongqiang Zhang
ZYZhao Yang
Zhao Yang
YTYuqin Tang
Yuqin Tang
CGChengbin Guo
Chengbin Guo
DLDanni Lin
Danni Lin
GLGen Li
Gen Li
The high risk of postoperative mortality in lung adenocarcinoma (LUAD) patients is principally driven by cancer recurrence and low response rates to adjuvant treatment. Here, A combined cohort containing 1,026 stage I–III patients was divided into the learning (n = 678) and validation datasets (n = 348). The former was used to establish a 16-mRNA risk signature for recurrence prediction with multiple statistical algorithms, which was verified in the validation set. Univariate and multivariate analyses confirmed it as an independent indicator for both recurrence-free survival (RFS) and overall survival (OS). Distinct molecular characteristics between the two groups including genomic alterations, and hallmark pathways were comprehensively analyzed. Remarkably, the classifier was tightly linked to immune infiltrations, highlighting the critical role of immune surveillance in prolonging survival for LUAD. Moreover, the classifier was a valuable predictor for therapeutic responses in patients, and the low-risk group was more likely to yield clinical benefits from immunotherapy. A transcription factor regulatory protein–protein interaction network (TF-PPI-network) was constructed via weighted gene co-expression network analysis (WGCNA) concerning the hub genes of the signature. The constructed multidimensional nomogram dramatically increased the predictive accuracy. Therefore, our signature provides a forceful basis for individualized LUAD management with promising potential implications.


10 March 2026 in Medicine Bulletin
Verified
Journal Article
Open access
YTYuqin Tang
Yuqin Tang
ZLZheng Luo
Zheng Luo
XZXu Zhao
Xu Zhao
ZYZhang Yongqiang
Zhang Yongqiang
MSMingyang Sun
Mingyang Sun
JZjiaqiang zhang
jiaqiang zhang
Traditional Chinese medicine (TCM), including herbal analgesic adjuvants and acupuncture‐based interventions, has gained increasing attention as an integrative strategy for perioperative pain management in oncology. Bioactive phytochemicals—such as terpenoids, flavonoids, alkaloids, and polyphenols—exert multimodal pharmacological effects relevant to perioperative analgesia through modulation of ion channels, GABAA receptors, inflammatory signaling pathways (MAPK/COX‐2), and redox homeostasis. In parallel, acupuncture activates endogenous analgesic systems, including opioid and monoaminergic descending inhibitory pathways, modulates autonomic balance via vagal anti‐inflammatory reflexes, and alters local perfusion, thereby influencing nociception and perioperative immune responses. Recent advances in nano‐enabled delivery systems—such as lipid and polymeric nanoparticles, micelles, enzyme‐responsive hydrogels, and acupoint‐targeted formulations—aim to overcome key pharmacokinetic limitations of phytochemicals by improving solubility, stability, and site‐selective release. These platforms may be combined with acupoint‐based approaches to enhance localized exposure in perioperative settings. Preclinical and early translational studies suggest that such integrative strategies can modulate nociceptive signaling and perioperative inflammatory or immune processes within the tumor microenvironment (TME). However, clinical translation remains limited. Most evidence is derived from animal models, small clinical studies, or nononcologic surgical populations, with substantial gaps in standardized formulations, pharmacokinetic and drug–drug interaction data, regulatory clarity, and randomized trials incorporating immunologic or oncologic end points. This narrative review critically synthesizes current mechanistic and emerging clinical evidence and outlines a translational roadmap emphasizing standardized analytics, integrated PK/toxicity assessment, biomarker‐informed patient stratification, and rigorously designed clinical trials to determine whether TCM modalities can safely provide opioid‐sparing analgesia without compromising perioperative immune function or oncologic outcomes.

20 September 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
BGBaojun Guo
Baojun Guo
YTYuqin Tang
Yuqin Tang
ZYZhang Yongqiang
Zhang Yongqiang
YWYeke Wu
Yeke Wu
RGRanran Gao
Ranran Gao
Background: Insomnia is a pathological sleep disorder marked by persistent sleep‐onset difficulties. This study explored the therapeutic effects and underlying mechanism of Banxia Shumi Decoction (BXSMD) in treating insomnia. Methods: This study used network pharmacology to predict the core targets and signaling pathways of BXSMD in insomnia intervention. A rat insomnia model was constructed via 4‐Chloro‐DL‐phenylalanine (PCPA) to assess BXSMD's behavioral impacts. ELISA, qRT‐PCR, Western blot, and IHC were applied to detect the expression of 5‐hydroxytryptamine (5‐HT), melatonin (MT), MT1/MT2 receptors, and related factors (CLOCK, PER1, CaMKII, p‐CREB/CREB, GABARAP, mGLuR1, ADAM10) in the rat suprachiasmatic nucleus (SCN), hippocampus, and serum. The non‐selective melatonin receptor antagonist luzindole was administered to explore its influence on BXSMD‐regulated expression of the above molecules. Results: Compared with the model group, the BXSMD group showed shortened sleep latency and prolonged sleep duration. BXSMD significantly elevated 5‐HT, MT, and MT1/MT2 levels. BXSMD upregulated the mRNA and protein expression of downstream effector molecules including CLOCK, PER1, CaMKII, and GABARAP, downregulated mGLuR1 expression, and increased the expression of ADAM10. Notably, CREB mRNA expression remained unchanged, while BXSMD significantly increased the p‐CREB/CREB protein ratio. The regulatory effects of BXSMD on all altered molecules were significantly reversed by luzindole. Conclusion: BXSMD effectively alleviates PCPA‐induced insomnia in rats. The mechanism relies on MT1/MT2 as core targets, which mediate the regulation of sleep‐related molecules (CLOCK, PER1, CaMKII, p‐CREB/CREB, GABARAP, and mGluR1), as well as the membrane protein shedding‐related molecule ADAM10.